Check 35,000+ stocks against 26 valuation models and 37 quality factors

Torrent Pharmaceuticals Limited (500420) fair value: what the stock is really worth

As of Oct 1, 2026: fair value of Torrent Pharmaceuticals Limited ₹5,490, price ₹4,762, upside +15.3%, quality 54 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

Fair value above price? Yes
Good quality? Yes
Add to watchlist

Healthcare · IN · ISIN INE685A01028

TP Some data Sep 24, 2026

Torrent Pharmaceuticals Limited

500420 · BSE

UndervaluedQuality growthThe stock appears undervalued with acceptable quality.

✓Fair value ₹5,490 · Undervalued (+15.3%)

!Quality 54/100

✓Healthy Growth (revenue 5y +11.4 %/yr)

✓Solidly profitable · 15.7% net margin (FY2025)

✓Moderate debt · generates free cash flow

✓Wide moat 67/100

!Evidence only medium, so the estimate is less certain

26 models, one by oneBear ₹2,691 to bull ₹9,051 Growth analysisrevenue history, year by year Quality 54/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Watch Torrent Pharmaceuticals Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range ₹1,196 – ₹5,103 · fair‑value band ₹2,691 – ₹9,051 · the ₹4,762 price screens below the ₹5,490 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Torrent Pharmaceuticals Limited engages in the research, development, manufacturing, and marketing of generic pharmaceutical formulations in India and internationally.

Torrent Pharmaceuticals Limited engages in the research, development, manufacturing, and marketing of generic pharmaceutical formulations in India and internationally. The company offers products in various therapeutic areas, including cardiovascular, central nervous system, gastrointestinal, diabetology, anti-infective, pain management, nephrology, oncology, gynecology, pediatric, wound care, and nutraceuticals. It also provides contract manufacturing services. The company was formerly known as Trinity Laboratories and changed its name to Torrent Pharmaceuticals Limited in 1971. The company was founded in 1959 and is based in Ahmedabad, India. Torrent Pharmaceuticals Limited is a subsidiary of Torrent Private Limited.

Stock analysis

Torrent Pharmaceuticals Limited (500420) currently trades at ₹4,762, while our model-based Fair Value estimate is ₹5,490, implying the stock looks roughly 13.3% undervalued today.

Valuation

Bull case: the DCF Models group reads highest at a median of ₹5,339 per share, and 14 of the 24 models we run sit above the ₹4,762 price.

Bear case: the Asset-Based group reads lowest at ₹690.27, and 10 of the 24 models stay below the price. Evidence for this calculation is medium.

Scenario range: ₹2,691 (bear) to ₹9,051 (bull), the price of ₹4,762 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 54/100 (solid quality), in the Healthcare sector.

Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.

Torrent Pharmaceuticals Limited reported revenue of ₹138B in FY2025 versus ₹85.1B in FY2021, a compound +12.8%/yr. Reported net income was ₹21.6B in FY2025, compounding +29.2%/yr from FY2021.

Key figures

Market cap ₹388B (≈ $4.0B) · P/E ratio 37.8 · P/S ratio 5.95 · EPS (TTM) ₹60.62 · Dividend yield 3.3% · Net margin 15.7% · Return on assets (EBIT) 13.6% · Free cash flow ₹23.5B.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 52 out of 100 (low confidence).

What moves the price

The share trades about 7% below its 52-week high and 37% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −40% fair-value upside, at 15%, 500420 screens cheaper than that median.

Fair Value models

Bear ₹2,691 Fair Value ₹5,490 Bull ₹9,051

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (₹45.84 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Highest evidence

FCF DCF ₹2,580 ₹5,339 ₹9,828 76

Growth DCF ₹2,562 ₹5,109 ₹9,120 75

Owner Earnings ₹2,960 ₹5,989 ₹10,918 73

All 24 models by family

DCF Models

FCF DCF ₹2,580 ₹5,339 ₹9,828 76

Owner Earnings ₹2,960 ₹5,989 ₹10,918 73

5Y Revenue Exit ₹2,312 ₹4,872 ₹8,294 70

5Y EBITDA Exit ₹3,565 ₹7,401 ₹12,157 72

5Y P/E Exit ₹2,664 ₹5,582 ₹8,853 68

10Y Revenue Exit ₹2,255 ₹4,663 ₹8,238 64

10Y EBITDA Exit ₹3,174 ₹6,454 ₹11,336 65

10Y P/E Exit ₹2,595 ₹5,166 ₹8,686 61

Earnings-Based

Graham-Dodd ₹1,807 ₹7,789 ₹10,646 64

Lynch FV ₹1,998 ₹2,854 ₹3,710 61

PEG = 1.0 ₹1,998 ₹2,854 ₹3,710 57

EPV ₹1,740 ₹2,219 ₹2,633 71

Multiples

P/E Multiple ₹4,384 ₹5,845 ₹7,307 63

P/S Multiple ₹3,388 ₹4,517 ₹5,646 58

P/B Multiple ₹3,388 ₹4,517 ₹5,646 55

EV/EBIT ₹4,093 ₹5,888 ₹7,684 65

EV/EBITDA ₹4,585 ₹6,545 ₹8,504 67

EV/Revenue ₹2,253 ₹3,774 ₹5,294 52

Asset-Based

NCAV (Graham) ₹515.13 ₹690.27 ₹1,030 54

Growth DCF

Growth DCF ₹2,562 ₹5,109 ₹9,120 75

Rev-Margin DCF ₹2,312 ₹4,825 ₹7,996 70

Economic Profit

Residual Income ₹1,561 ₹2,123 ₹3,996 72

ROIC Compounder ₹1,996 ₹3,064 ₹4,485 70

Growth Earnings

Growth-Adj P/E ₹3,427 ₹4,895 ₹6,364 67

Open the full fair value analysis →

Notify me when 500420 reaches fair value

Put 500420 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 54/100

Of which business quality 52 · Market factors (momentum, volatility) 70

Profitability 51

Margins and returns on capital today

Quality Growth 40

Are margins and returns improving?

Cashflow 70

Earnings quality: real cash, not paper profit

Fin. Strength 27

Balance sheet, leverage, solvency risk

Investment 44

Disciplined investing over empire-building

Low Volatility 83

Calm price path (market factor)

Momentum 59

Price trend over the last 3–12 months (market factor)

52W Momentum 74

Distance to the 52-week high (market factor)

Net Issuance 82

Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 84/100

Revenue growth appears healthy and is supported by profitability and cash-flow quality.

Revenue growth 1 year

+19.4%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+12.7%

Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+11.4%

Start year 2020 (pandemic). Over 10 years: +7.5% a year

Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+7.5%

’15

’16

’17

’18

’19

’20

’21

’22

’23

’24

’25

What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.

+14.9%

Earnings growth per share plus dividend.

Earnings per share, growth per year+11.6%

Dividend (yield on the price)3.3%

Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.11.6% vs 1.5%, picking up

Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.23% → 25%

Start year 2020 (pandemic)

Growth Forecast

A lot of optimism in the price

The price assumes more growth than the company has delivered so far.

What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).

+43.0%

Yearly growth needed for the next five years to justify today's price.

What forecasts expect

n/a

No analyst forecast available.

After inflation (India: IMF forecast 4.1% a year to 2030, 4.7% from 2016 to 2025) that is about +37.3% a year for the price.

Watch 500420, get fair value alerts →

Compare Torrent Pharmaceuticals Limited with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceuticals · 53 stocks

Beats the industry median on 5/12 measures

A mixed picture versus its industry peers.

Valuation

Quality Score 54 · Above median

Fair Value upside −75.9% · Bottom 25%

Profitability

Return on assets 0.0% · Below median

Net margin (TTM) 0.0% · Bottom 25%

Operating margin (TTM) 0.0% · Bottom 25%

Growth and dividend

Revenue growth 0.0% · Below median

Dividend yield (TTM) 3.3% · Top 25%

Balance sheet

Debt / equity 1.39× · Highest 25%

Valuation Multiplesvs Pharmaceuticals median · lower = cheaper

P/E (TTM) 37.8× · Priciest 25%

P/B 0.05× · Cheapest 25%

P/FCF 0.2× · Cheapest 25%

EV/EBITDA 3.8× · Cheapest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Pharmaceuticals stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value
Caregen Co 214370	40,850 KRW	5,414 KRW	−87%
ST Pharm Co 237690	91,700 KRW	50,110 KRW	−45%
Oscotec Inc 039200	35,650 KRW	21,262 KRW	−40%
DongKook Pharmaceutical Co 086450	22,150 KRW	28,372 KRW	+28%
SHUKRAPHAR SHUKRAPHAR	₹55.87	₹9.09	−84%
Huons Global Co 084110	22,950 KRW	46,562 KRW	+103%
BINEX Co 053030	6,490 KRW	1,844 KRW	−72%
Kolon Life Science Inc 102940	14,800 KRW	37,129 KRW	+151%
VIKRAMTH VIKRAMTH	₹405.90	₹444.16	+9%
JW Shinyak Corporation 067290	2,990 KRW	1,326 KRW	−56%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Run the numbers yourself: free valuation calculators

DCF Calculator Graham Number Peter Lynch Formula DDM Calculator Fama-French Model Intrinsic Value

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Torrent Pharmaceuticals Limited · Fair Value
₹5,490 +13%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/500420" target="_blank" rel="nofollow noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">Torrent Pharmaceuticals Limited · Fair Value</span><br><b style="font-size:20px">₹5,490</b> <span style="color:var(--fvc-g-mitte);font-weight:700;font-size:14px">+13%</span></span><span style="font-size:11px;color:var(--fvc-g-mitte);font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "Torrent Pharmaceuticals Limited Fair Value". https://www.fairvalue-calculator.com/stock/500420

Frequently asked questions

Is Torrent Pharmaceuticals Limited (500420) overvalued or undervalued?

As of Sep 24, 2026, our model estimates a fair value of ₹5,490 versus a price of ₹4,762, about +15% upside (undervalued).

What is the fair value of 500420?

Our model-based fair value for Torrent Pharmaceuticals Limited is ₹5,490 (as of Sep 24, 2026), built from audited fundamentals. The current price: ₹4,762.

What is the quality score of 500420?

Torrent Pharmaceuticals Limited has a Quality Score of 54/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for Torrent Pharmaceuticals Limited (500420)?

Our model-based price target is the fair value of ₹5,490 (as of Sep 24, 2026) from 24 valuation models. Cautious scenario ₹2,691, optimistic scenario ₹9,051. It is a calculation from audited fundamentals, not an analyst target.

What is the Torrent Pharmaceuticals Limited stock forecast for 2026?

Our models put fair value at ₹5,490, about +15% upside versus a price of ₹4,762 (undervalued). Cautious scenario ₹2,691, optimistic scenario ₹9,051. The calculation is refreshed regularly with new filings.

Does Torrent Pharmaceuticals Limited pay a dividend?

Torrent Pharmaceuticals Limited currently shows a dividend yield of about 3.32% relative to its recent price (as of Sep 24, 2026).

What growth is priced into Torrent Pharmaceuticals Limited (500420)?

For today's price to be fair in a discounted-cash-flow model, Torrent Pharmaceuticals Limited would have to grow free cash flow by +43.0 % per year for five years (discount rate 12.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +11.4 % per year. As of Sep 24, 2026.

What discount rate (WACC) does the fair value of 500420 use?

Our models discount Torrent Pharmaceuticals Limited at 12.4 %: a base by market capitalisation (mid), country premium for India. The same rate applies in all 26 models.

What is a reverse DCF?

A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Torrent Pharmaceuticals Limited that is +43.0 % per year a year over ten years, using the same discount rate (12.4 %) and the same formula as our fair value.

How much growth has Torrent Pharmaceuticals Limited (500420) delivered so far?

Over the past 5 years revenue at Torrent Pharmaceuticals Limited grew +11.4 % a year. The price currently implies +43.0 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.

How fast is the sector of Torrent Pharmaceuticals Limited (500420) growing?

The median revenue growth in the sector is +5.1 % a year. That is the yardstick for the growth priced into Torrent Pharmaceuticals Limited (+43.0 % per year a year): it shows whether the expectation is within the usual range or beyond it.

What is the free cash flow yield of Torrent Pharmaceuticals Limited (500420)?

The free-cash-flow yield on the price is 1.46 %: that much free cash flow Torrent Pharmaceuticals Limited produces per unit of market value. When it exceeds the discount rate of our models (12.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.

What is the intrinsic value of Torrent Pharmaceuticals Limited (500420)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Torrent Pharmaceuticals Limited it is ₹5,490 per share (as of Sep 24, 2026), against a price of ₹4,762. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).

Is Torrent Pharmaceuticals Limited stock overvalued or undervalued in 2026?

As of Sep 24, 2026, 500420 trades below its calculated fair value: price ₹4,762, fair value ₹5,490, a gap of about +15% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of 500420?

No. The price is what the market pays today (₹4,762); the fair value is what the company's own numbers justify (₹5,490). For Torrent Pharmaceuticals Limited the two are ₹728.15 per share apart. That gap is exactly why we show both numbers side by side.

How much is Torrent Pharmaceuticals Limited worth?

The market values Torrent Pharmaceuticals Limited at about ₹388B (market capitalisation, as of Sep 24, 2026). Per share that is ₹4,762; our models calculate a fair value of ₹5,490 per share.

What do the bullish and bearish scenarios say about 500420?

Our models span a range for Torrent Pharmaceuticals Limited: cautious scenario ₹2,691, base ₹5,490, optimistic ₹9,051 per share (as of Sep 24, 2026, price ₹4,762). The range comes from different growth and margin assumptions, not from analyst opinions.

What is the P/E ratio of 500420?

Torrent Pharmaceuticals Limited trades at a price-to-earnings ratio of 37.8 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹5,490 is built from several models across several years. Other multiples: P/B 0.1, EV/EBITDA 3.8.

How solid is the balance sheet of Torrent Pharmaceuticals Limited (500420)?

Balance-sheet figures for Torrent Pharmaceuticals Limited (as of Sep 24, 2026): debt of 1.39 per unit of equity. They feed the Quality Score of 54/100, which measures business quality independently of the share price.

How far is 500420 from its 52-week high?

Torrent Pharmaceuticals Limited trades at ₹4,762, about 7% below its 52-week high of ₹5,103 and 37% above the low of ₹3,483 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of ₹5,490 is for.

Which stocks are comparable to Torrent Pharmaceuticals Limited?

From the same area (Healthcare) we also value Caregen Co, ST Pharm Co, Oscotec Inc, DongKook Pharmaceutical Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is Torrent Pharmaceuticals Limited stock attractive at the current price?

The data as of Sep 24, 2026: price ₹4,762, calculated fair value ₹5,490 (+15%), Quality Score 54/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of 500420 calculated?

We run Torrent Pharmaceuticals Limited through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹5,490, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 14.5 % above its aggregate fair value. Torrent Pharmaceuticals Limited currently trades 13 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of Torrent Pharmaceuticals Limited (500420)?

The closing price on Oct 1, 2026 was ₹4,762. Our model-based fair value is ₹5,490, about +15% upside (undervalued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with Torrent Pharmaceuticals Limited right now?

The model range is unusually wide (₹2,691 to ₹9,051). The outcome hinges heavily on assumptions, so read the point estimate with caution. The price sits in the lower half of our model range, the side with the larger margin of safety. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.

Key figures of Torrent Pharmaceuticals Limited

How large is the market capitalisation of Torrent Pharmaceuticals Limited (500420)?

The market capitalisation of Torrent Pharmaceuticals Limited is ₹388B (≈ $4.0B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What is the P/S ratio of Torrent Pharmaceuticals Limited (500420)?

The price-to-sales ratio of Torrent Pharmaceuticals Limited is 5.95 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.

What are the earnings per share of Torrent Pharmaceuticals Limited (500420)?

Earnings per share at Torrent Pharmaceuticals Limited are ₹60.62 (price ÷ EPS = P/E 37.8). Earnings per share over the last twelve months: total profit spread across every single share.

What is the dividend yield of Torrent Pharmaceuticals Limited (500420)?

The dividend yield of Torrent Pharmaceuticals Limited is 3.3%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.

What is the net margin of Torrent Pharmaceuticals Limited (500420)?

The net margin of Torrent Pharmaceuticals Limited is 15.7% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.

What is the EBIT return on assets of Torrent Pharmaceuticals Limited (500420)?

On an EBIT basis the return on assets of Torrent Pharmaceuticals Limited is 13.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

How much net debt does Torrent Pharmaceuticals Limited (500420) carry?

The net debt of Torrent Pharmaceuticals Limited is ₹137B (fiscal year 2025, ≈ 5.8 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.

Free · no account needed

Watch Torrent Pharmaceuticals Limited in the live analysis

One click puts Torrent Pharmaceuticals Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.